{"id":48361,"date":"2024-08-12T13:59:40","date_gmt":"2024-08-12T13:59:40","guid":{"rendered":"https:\/\/i-base.info\/htb\/?p=48361"},"modified":"2024-08-12T16:44:16","modified_gmt":"2024-08-12T16:44:16","slug":"bms-to-discontinue-atazanavir-cobicistat-evotaz-in-september-2024","status":"publish","type":"post","link":"https:\/\/i-base.info\/htb\/48361","title":{"rendered":"BMS to discontinue atazanavir\/cobicistat (Evotaz) in September 2024"},"content":{"rendered":"<p><strong>Simon Collins, HIV i-Base<\/strong><\/p>\n<p><strong>In July 2024, Bristol Myers Squibb (BMS) announced plans to discontinue the coformulation of atazanavir\/cobicistat (Evotaz) on 30 September 2024.<\/strong><\/p>\n<p>This is due to declining sales and the availability of newer options for ART.<\/p>\n<p>It is also due to availability of generic versions of each drug.<\/p>\n<p>Doctors are being asked to review anyone currently receiving atazanavir\/cobicistat as part of their antiretroviral regimen.<\/p>\n<p>Please contact the BMS Medical Information Department for further information <a href=\"mailto:medical.information@bms.com\">by email<\/a> or call 0800 731 1736.<\/p>\n<p>\n<\/p>","protected":false},"excerpt":{"rendered":"<p>Simon Collins, HIV i-Base In July 2024, Bristol Myers Squibb (BMS) announced plans to discontinue the coformulation of atazanavir\/cobicistat (Evotaz) on 30 September 2024. This is due to declining sales and the availability of newer options for ART. It is &hellip;<\/p>\n","protected":false},"author":3,"featured_media":0,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[3],"tags":[],"class_list":["post-48361","post","type-post","status-publish","format-standard","hentry","category-antiretrovirals"],"_links":{"self":[{"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/posts\/48361","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/comments?post=48361"}],"version-history":[{"count":8,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/posts\/48361\/revisions"}],"predecessor-version":[{"id":48399,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/posts\/48361\/revisions\/48399"}],"wp:attachment":[{"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/media?parent=48361"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/categories?post=48361"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/tags?post=48361"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}